EA201200617A1 - Полимеры на основе циклодекстрина для доставки лекарственных средств - Google Patents

Полимеры на основе циклодекстрина для доставки лекарственных средств

Info

Publication number
EA201200617A1
EA201200617A1 EA201200617A EA201200617A EA201200617A1 EA 201200617 A1 EA201200617 A1 EA 201200617A1 EA 201200617 A EA201200617 A EA 201200617A EA 201200617 A EA201200617 A EA 201200617A EA 201200617 A1 EA201200617 A1 EA 201200617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclodextrine
medicines
polymers
delivery
basis
Prior art date
Application number
EA201200617A
Other languages
English (en)
Inventor
Марк Вольфганг
Лоренс А. Райтер
Томас С. Кроуфорд
Оливер С. Фетцер
Original Assignee
Серулин Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Серулин Фарма Инк. filed Critical Серулин Фарма Инк.
Publication of EA201200617A1 publication Critical patent/EA201200617A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups

Abstract

В данной заявке описаны способы и композиции, относящиеся к конъюгатам CDP-таксан.
EA201200617A 2009-11-23 2010-11-23 Полимеры на основе циклодекстрина для доставки лекарственных средств EA201200617A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26374909P 2009-11-23 2009-11-23
US39192210P 2010-10-11 2010-10-11
PCT/US2010/057913 WO2011063421A1 (en) 2009-11-23 2010-11-23 Cyclodextrin-based polymers for therapeutic delivery

Publications (1)

Publication Number Publication Date
EA201200617A1 true EA201200617A1 (ru) 2012-11-30

Family

ID=44060087

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200617A EA201200617A1 (ru) 2009-11-23 2010-11-23 Полимеры на основе циклодекстрина для доставки лекарственных средств

Country Status (11)

Country Link
US (1) US20110237540A1 (ru)
EP (1) EP2503888A4 (ru)
JP (3) JP6220126B2 (ru)
CN (3) CN104208716A (ru)
AU (1) AU2010321533A1 (ru)
BR (1) BR112012012210B8 (ru)
CA (1) CA2781669A1 (ru)
EA (1) EA201200617A1 (ru)
IL (1) IL219699B (ru)
MX (1) MX2012005987A (ru)
WO (1) WO2011063421A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
BR112012011457A2 (pt) 2009-10-29 2016-05-03 Aventis Pharma Sa uso antitumoral de cabazitaxel.
US20120058971A1 (en) * 2009-11-23 2012-03-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
AU2011255647A1 (en) * 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
IN2014DN02060A (ru) * 2011-09-15 2015-05-15 Novartis Ag
CN104203985A (zh) * 2012-01-31 2014-12-10 天蓝制药公司 用于治疗性递送的环糊精类聚合物
US20130196946A1 (en) * 2012-01-31 2013-08-01 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CN103242267B (zh) * 2012-02-03 2015-03-18 福建南方制药股份有限公司 卡巴他赛及其中间体的制备方法及卡巴他赛中间体
AU2013217964A1 (en) * 2012-02-10 2014-08-28 Aventis Pharma S.A. New pediatric uses of cabazitaxel
EP2838653A4 (en) 2012-04-18 2015-11-25 Cerulean Pharma Inc METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND PARTICLE GENERATION
WO2014004651A1 (en) * 2012-06-26 2014-01-03 The Johns Hopkins University Multifunctional tunable biomaterials for tissue engineering
WO2014015422A1 (en) * 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
AU2014273983A1 (en) * 2013-05-31 2015-12-17 Cerulean Pharma Inc. Cyclodextrin-based polymers for the therapeutic delivery
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10980765B2 (en) * 2015-08-14 2021-04-20 Board Of Supervisors Of Louisiana State University Isothiocyanatostilbenes as a novel method and product for treating cancer
JP2019535827A (ja) * 2016-11-16 2019-12-12 アイビタ バイオメディカル インコーポレイテッド 細胞膜結合シグナル伝達因子の使用
JP2021503477A (ja) 2017-11-16 2021-02-12 アイビタ バイオメディカル インコーポレイテッド 細胞膜結合シグナル伝達因子の使用
CN111440253B (zh) * 2019-01-17 2021-08-27 中国科学院上海药物研究所 立方形环糊精骨架-rgd组合物及其制备方法
WO2021034335A1 (en) * 2019-08-16 2021-02-25 Odonate Therapeutics, Inc. Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472835A (en) * 1964-02-12 1969-10-14 American Mach & Foundry Schardinger dextrins
US3454530A (en) * 1966-03-07 1969-07-08 Leslie C Case Novel polyols which are reaction products of a monoepoxide and a cyclic monoanhydride
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) * 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3654261A (en) * 1968-06-27 1972-04-04 Cpc International Inc Quaternary ammonium alkoxide alkoxy polyol compounds
USRE32268E (en) * 1973-03-01 1986-10-21 Strategic Medical Research Corp. Therapeutic composition and method of therapeutically treating warm blooded animals therewith
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
DE2842862A1 (de) * 1978-10-02 1980-04-10 Boehringer Mannheim Gmbh Verfahren zur bestimmung von ionen, polaren und/oder lipophilen substanzen in fluessigkeiten
CA1190855A (en) * 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4570629A (en) * 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
ATE26584T1 (de) * 1983-07-01 1987-05-15 Battelle Memorial Institute In-vivo abbaubares polypeptid und dessen anwendung zur verzoegerten freigabe von medikamenten.
US4525495A (en) * 1983-07-22 1985-06-25 The Dow Chemical Company Mineral filled composites
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4841081A (en) * 1985-10-16 1989-06-20 Osaka Soda Co., Ltd. Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
AU624077B2 (en) * 1987-06-17 1992-06-04 Institute For Child Health Research Cloning of mite allergens
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US4941996A (en) * 1987-10-19 1990-07-17 Minnesota Mining And Manufacturing Company Inclusion complexes providing second harmonic generation
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JP2614081B2 (ja) * 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
US4887778A (en) * 1988-06-01 1989-12-19 Universal Instruments Corporation Feeder drive assembly and replaceable section for tape supplying and cover peeling
US4902788A (en) * 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
US5098793A (en) * 1988-09-29 1992-03-24 Uop Cyclodextrin films on solid substrates
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
DE4009825A1 (de) * 1990-03-27 1991-10-02 Consortium Elektrochem Ind Wasserunloesliche cyclodextrin-polymerisate und verfahren zu deren herstellung
JPH0425505A (ja) * 1990-05-21 1992-01-29 Toppan Printing Co Ltd シクロデキストリンポリマー及びシクロデキストリン膜の製造方法
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
WO1992006127A1 (fr) * 1990-10-01 1992-04-16 Toppan Printing Co., Ltd. Polymere de cyclodextrine et film de cyclodextrine forme a partir de celui-ci
CA2066633A1 (en) * 1990-11-30 1992-05-31 Masanobu Yoshinaga Processes for producing cyclodextrin derivatives and polymers containing immobilizing cyclodextrin therein
US5148854A (en) * 1990-12-11 1992-09-22 Toshiba Kikai Kabushiki Kaisha Counting die cast manufactured goods
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5750561A (en) * 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) * 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
AU3124793A (en) * 1991-10-29 1993-06-07 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (ru) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5219980A (en) * 1992-04-16 1993-06-15 Sri International Polymers biodegradable or bioerodiable into amino acids
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
JPH07503757A (ja) * 1992-11-30 1995-04-20 バイオ・キュア・インコーポレーテッド 重合性炭水化物エステル，それから得られるポリマー及びその用途
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
ATE264671T1 (de) * 1993-02-22 2004-05-15 American Bioscience Inc Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
TW328535B (en) * 1993-07-02 1998-03-21 Novartis Ag Functional photoinitiators and their manufacture
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5880154A (en) * 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
TW307775B (en) * 1994-02-15 1997-06-11 Novartis Erfind Verwalt Gmbh Unsaturated carbohydrate derivatives, polymers thereof and their use
HU218280B (en) * 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
US5691316A (en) * 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
US5679773A (en) * 1995-01-17 1997-10-21 Affymax Technologies N.V Reagants and methods for immobilized polymer synthesis and display
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
JPH10507160A (ja) * 1994-06-23 1998-07-14 アフィマックス テクノロジーズ エヌ．ブイ． 光活性化合物およびその使用方法
JP3699141B2 (ja) * 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6372780B2 (en) * 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69735057T2 (de) * 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
US5844030A (en) * 1996-07-09 1998-12-01 Andros; Nicholas Charged ion cleaning devices and cleaning system
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
AU7124598A (en) * 1997-04-18 1998-11-13 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
AU749032B2 (en) * 1997-06-13 2002-06-20 Johns Hopkins University, The Therapeutic nanospheres
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JPH11100401A (ja) * 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
US6410342B1 (en) * 1997-08-19 2002-06-25 Pharmacopeia, Inc. Method and apparatus for controlled photoelution
CN100391542C (zh) * 1997-09-15 2008-06-04 遗传免疫有限公司 向抗原呈递细胞递送基因的药物组合物及其用途
GB9801109D0 (en) * 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
DE69909972T2 (de) * 1998-02-11 2004-05-13 University Of Houston, Houston Vorrichtung zur durchführung chemischer und biochemischer reaktionen unter anwendung von photoerzeugten reagenzien
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
JP2001288097A (ja) * 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003020305A1 (en) * 2001-08-30 2003-03-13 Baylor College Of Medecine Methionine restriction for cancer therapy
AU2003239121A1 (en) 2002-02-22 2003-09-09 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
KR20140070676A (ko) * 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
CN1694728B (zh) * 2002-09-06 2011-12-28 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
CA2501132A1 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
TW200613515A (en) * 2004-06-26 2006-05-01 Merck Patent Gmbh Compounds for organic electronic devices
PL1811979T3 (pl) * 2004-09-27 2009-04-30 Sigmoid Pharma Ltd Mikrokapsułki zawierające metyloksantynę i kortykosteroid
JO2596B1 (en) 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
EP2121681B1 (en) * 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer

Also Published As

Publication number Publication date
CA2781669A1 (en) 2011-05-26
BR112012012210B8 (pt) 2021-05-25
JP2013511558A (ja) 2013-04-04
JP2016216508A (ja) 2016-12-22
WO2011063421A1 (en) 2011-05-26
CN107261150A (zh) 2017-10-20
CN104208716A (zh) 2014-12-17
CN102781237A (zh) 2012-11-14
IL219699A0 (en) 2012-07-31
BR112012012210A2 (pt) 2015-09-08
EP2503888A4 (en) 2015-07-29
AU2010321533A1 (en) 2012-05-31
BR112012012210B1 (pt) 2021-02-09
EP2503888A1 (en) 2012-10-03
JP6220126B2 (ja) 2017-10-25
US20110237540A1 (en) 2011-09-29
MX2012005987A (es) 2012-06-25
IL219699B (en) 2018-10-31
JP2015071624A (ja) 2015-04-16

Similar Documents

Publication Publication Date Title
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
JOP20180102B1 (ar) مركب صيدلاني
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BRPI1010768A2 (pt) composto, e, composição farmacêutica.
EA201170227A1 (ru) Имидазолкарбоксамиды
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
DK2651436T3 (da) Mycobakterie antigen sammensætning.
EA201001710A3 (ru) Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин
MA34025B1 (fr) Polypeptides se liant au bêta-a
WO2011057262A3 (en) Treatment of infections with tp receptor antagonists
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
BR112014025041B8 (pt) Composição farmacêutica
EA201290642A1 (ru) Соединения и способы
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BRPI0923583A2 (pt) síntese de conjugados de polímeros de compostos de indocarbzol.
TR200900882A2 (tr) Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler.
CL2009001973S1 (es) Mostrador.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
TR201007106A1 (tr) Sefpodoksim proksetil formülasyonları.
EP2569327A4 (en) EIF4E BINDING PEPTIDES